PATENT CLAIM ANALYSIS

Application Number: 15890431
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "134100"]

Abstract:
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.

Claim (Index 7):
A method for altering the phenotypic presentation of abnormal morphology or lack of sweat glands associated with ectodermal dysplasia in a mammalian organism diagnosed with or suspected of having ectodermal dysplasia comprising, administering to said mammalian organism a pharmaceutical composition comprising a hexamer of recombinant proteins, each of said proteins consisting of the amino acid sequence of SEQ ID NO: 1, wherein the pharmaceutical composition is administered to the organism at a time period of after week 8 of gestation, or after birth.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.39216
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14861292', '14117431', '15030502', '13260937', '13791055']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7565621915343282
- 35 USC 102 Novelty (BERT): 0.6462729945612535
- Combined Prediction Score: 0.7455332718370208
- Mean Citation Score: 495.17748200000005
- Max Citation Score: 676.22015
- Similarity Product: 559.2653562313378

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test